Idrapril, the prototype of a new clinical class of ACE inhibitors, has a pharmacological profile similar to captopril in animals. Preliminary experimental data suggest a lower potential for inducing cough compared to captopril. In humans, it has a short elimination half-life of about 2 h, but a much longer effect on RAS and blood pressure (12 to 24 h), without affecting heart rate.
|Number of pages||13|
|Journal||Cardiovascular Drug Reviews|
|Publication status||Published - 1996|
- Angiotensin-converting enzyme inhibitor
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine